The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m 2 with auto-SCT of G-CSF-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR þ very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan-Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8 þ cytotoxic T cell and CD56 þ natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster.
Introduction
The role of high-dose chemotherapy (HDCT) with auto-SCT in the treatment of multiple myeloma was established by the IFM90 and MRC VII studies, which showed the superiority of this approach over conventional cytotoxic chemotherapy. 1, 2 Although improvements in disease-free and overall survival (OS) are observed with auto-SCT, the majority of patients relapse within 3 years of therapy and few, if any, patients are cured of their disease. As a result, there is a great interest in developing therapeutic strategies that can further improve outcomes. In recent years, regimens using the proteasome inhibitor bortezomib and immunomodulatory drugs have shown impressive response rates in patients with relapsed or refractory multiple myeloma. [3] [4] [5] [6] Yet questions remain on how to integrate these newer anti-myeloma agents into the transplant paradigm.
Bortezomib has been used either alone or in novel combinations during pre-auto-SCT induction therapy to improve complete and overall response rates. [7] [8] [9] [10] However, no study has reported on the use of bortezomib maintenance therapy after HDCT. In the present trial, we sought to test the safety and efficacy of an approach in which bortezomib is administered sequentially before HDCT and also as maintenance therapy after transplant. Because of the potential immunomodulatory effects of bortezomib, we also conducted exploratory studies on PBL subsets during bortezomib therapy.
Methods

Patients
Patients diagnosed with multiple myeloma were enrolled in this trial before treatment with HDCT and auto-SCT at the Washington University School of Medicine. Patients received induction therapy at the discretion of the referring oncologist. Patient's age X18 years, ECOG/Zubrod performance status p2, and acceptable baseline organ function (platelets 4100 000/mm 3 , hemoglobin 48 g/ 100 ml, ANC 41500/mm 3 , AST, ALT p3 Â ULN, total bilirubin p2 Â upper limit of normal, and creatinine clearance X20 ml/min) were eligible for the study. Individuals with amyloidosis, peripheral neuropathy XNCI grade 2 or those treated earlier with 45 cycles of an anthracycline or 41 cycle of high-dose CY or other alkylator-based regimen were excluded. This study was approved by the Institutional Review Board of Washington University with all patients providing informed consent according to institutional standards before treatment. 
Study design and treatment schedule
CD34
þ cells/kg recipient body weight was achieved. Thereafter, patients were conditioned with high-dose melphalan 100 mg/m 2 /day Â 2 days followed by reinfusion of PBSCs. GM-CSF 250 mg/m 2 was administered post transplant until neutrophil engraftment. Beginning at 90-120 days post transplant, maintenance therapy consisting of bortezomib 1.3 mg/m 2 was administered weekly for 4 of every 5 weeks for up to six cycles. Responses were assessed according to the International Uniform Response Criteria. 11 Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)H v3.0.
12 Antiviral prophylaxis was administered until neutrophil engraftment.
CD34 and lymphocyte subset analysis CD34 þ cells were enumerated using a single platform, lyse, no wash system according to International Society of Hematotherapy and Graft Engineering protocols. 13 Peripheral blood was collected at baseline (cycle 1, day 1) and after two cycles of pre-transplant bortezomib (cycle 2, day 21) for lymphocyte subset analysis by multicolor flow cytometry (FC500, Beckman Coulter) gated on the CD45 bright , side scatter low population.
End points and statistics
The primary objective was to study the effect of bortezomib administered before stem cell mobilization on the yield of CD34 þ stem cells in the first apheresis product. Secondary objectives were to (i) evaluate the time to PFS and diseasefree survival for these patients who also received bortezomib after auto-SCT, (ii) evaluate the toxicity of bortezomib used before mobilization and after auto-SCT and (iii) determine the effects of bortezomib on the content of CD34 and lymphocyte subsets in the peripheral blood. Differences between baseline and post-bortezomib PBL subsets were analyzed by the Wilcoxon signed-rank test. Response rates and Kaplan-Meier estimates of EFS and OS were conducted on an intention-to-treat basis. appropriate for HDCT (Table 1) . Of the 40 patients, 38 received induction chemotherapy before their first dose of bortezomib with the most common induction regimens being doxorubicin, vincristine and dexamethasone (VAD or DVd regimen) or thalidomide and dexamethasone. Treatment with bortezomib began at a median of 120 days (range 0-392) post-induction chemotherapy. Median time from diagnosis to the start of induction chemotherapy was 14 days (range 0-44 months).
Results
Patient population
Pre-transplant bortezomib
Of the 40 enrolled patients, 39 completed two cycles of pre-transplant bortezomib ( Figure 2 ). One early discontinuation occurred during the first cycle of therapy because of rapidly progressive disease. One additional patient did not proceed to stem cell collection because of cerebrovascular ischemia occurring during G-CSF mobilization. Thirty-one patients had measurable monoclonal protein levels at diagnosis, before and after pre-transplant bortezomib. For these patients, their M-protein decreased from a median of 2.6 g/100 ml (range 0-8.45) at the start of induction, to 1.05 g/100 ml (0-4.8) before pretransplant bortezomib and to 0.85 g/100 ml (0-3.3) after two cycles of bortezomib. Response assessment immediately before stem cell mobilization showed a CR þ very good partial remission (VGPR) in six patients (15%) and partial remission (PR) in another 22 patients (55%). Six patients (19%) experienced a 475% reduction in monoclonal protein with an additional three patients (10%) having a 25-75% decrease during their pre-transplant bortezomib. Peripheral blood subset analysis PBL subsets analysis at baseline and after two cycles of pretransplant bortezomib revealed a 38% decrease in the absolute number of circulating natural killer cells
þ , P ¼ 0.022). The CD4/CD8 ratio increased by 26% (P ¼ 0.0006), which was secondary to a decrease in the absolute number of cytotoxic T cells (CD45
þ , P ¼ 0.055; Table 2 ). Changes in T-cell subsets occurred without any significant change in total lymphocyte counts.
Stem cell collection and HDCT
The successful collection of 2.5 Â 10 6 CD34 þ /kg G-CSFmobilized PBSCs was achieved in 37 of 38 patients. Twentynine (76%) patients required a single day for collection and in 36 patients (95%) collection was completed within 2 days, with a median first collection of 4.24 Â 10 6 CD34 þ /kg ( Figure 3 ). The single patient who failed stem cell harvest had recently undergone pelvic irradiation for a symptomatic lytic bone lesion and had a prior history of breast cancer treated with adjuvant chemoradiation.
The remaining 37 patients underwent high-dose melphalan with auto-SCT. Neutrophil engraftment (ANC X500/ mm 3 ) was rapid post transplant occurring at a median of 11 days (range 9-14). Median time to platelet engraftment (platelets X20 000/m 3 sustained for 7 days without transfusion) also occurred at 11 days (range 9-31; Figure 4) .
Response assessment 90-120 days after HDCT showed CR þ VGPR in 17 patients (43%) and PR in 14 patients (35%). In addition, seven patients (18%) had stable disease and two patients (5%) showed disease progression at this time (Table 3) .
Post transplant bortezomib
Of the 40 enrolled patients, 28 received post transplant bortezomib. During post transplant bortezomib, the response of one patient improved from VGPR to CR and that of an additional patient improved from PR to VGPR. The median follow-up of the surviving patients is 838 days (range 550-1116). By intention to treat, a VGPR þ CR rate of 43% with an overall response rate (PR þ VGPR þ CR) of 73% was observed with the study protocol. The best response achieved at any time during the treatment protocol was CR þ VGPR in 50% and PR in 33%.
Survival analysis
The median follow-up of the entire cohort is currently 795 days (range 273-116) with 29 patients alive and 11 patients deceased because of progressive disease. In an intention-totreat analysis, the Kaplan-Meier estimate of the median EFS was 770 days (range 191-1446) from the start of any induction chemotherapy as the baseline and 607 days (range 5-1116) from the start of pre-transplant bortezomib with a 3-year Kaplan-Meier estimate of EFS of 38.2 and 32.3%, respectively ( Figure 5 ). Median OS has not been reached with a 3-year Kaplan-Meier estimate of OS of 63.1% from the start of induction therapy and 62.2% from the start of bortezomib. No differences in either EFS or OS were observed in patients who achieved at least a VGPR versus those who did not with their autologous transplant (EFS hazard ratio 0.4874, 95% CI: 0.3125-1.741, P ¼ 0.67; OS hazard ratio 0.8602, 95% CI: 0.26-2.8, P ¼ 0.80).
Adverse events
The most common adverse events during pre-and post transplant bortezomib were grade 1 fatigue in 17/40 (43%) patients and grades 1-2 pain in 18/40 (45%) patients. Twenty-one patients (53%) experienced neuropathy during the study protocol including five (13%) patients with grades 3-4 neuropathy. Treatment-emergent neuropathy occurred in three (8%) patients during the pre-transplant phase and four (10%) patients during the post transplant bortezomib (Table 4) . Of those experiencing treatment-emergent Table 2 Lymphocyte subsets at baseline and after two cycles of bortezomib neuropathy, bortezomib was discontinued in two patients and the dose reduced in an additional two patients. One patient developed cerebrovascular ischemia during G-CSF mobilization, which was judged to be unrelated to bortezomib administration. No other grades 3-4 toxicities were observed during bortezomib administration.
In addition to neuropathy, herpes virus infections were common, with 15 (38%) patients developing reactivation of varicella zoster at a median of 206 days from the start of the study (range 25-375 days). Thirteen cases (33%) occurred post transplant with nine (23%) occurring during bortezomib consolidation.
Discussion
This is the first study to report on the feasibility and efficacy of an approach in which bortezomib is administered sequentially pre-transplant and as maintenance post transplant. This study was initiated before the commercial availability of bortezomib. Because of local referral patterns, we allowed the enrollment of patients who had received induction therapy with community oncologists 3 ) and platelet engraftment (platelets X20 000/mm 3 sustained for 7 days without transfusion) post stem cell infusion after high-dose melphalan (n ¼ 37). Table 3 Response evaluation (n ¼ 40)
Post transplant (+90 to 120 days) End of the treatment Best overall response n (%) n (%) n (%) before referral to our transplant center. The modest effect of bortezomib on paraprotein levels when given subsequent to pre-transplant may reflect the short (2-cycle) exposure and possibly the proliferation characteristics of the cell residual malignant cells. The effect on the subsequent collection of autologous stem cells remains an important consideration in the choice of initial therapy in multiple myeloma. Our study complements reports of successful stem cell collection after treatment with bortezomib using chemotherapy þ G-CSF and G-CSF alone for mobilization of stem cells. 9 In contrast, recent studies indicate that lenalidomide adversely affects stem cell mobilization. Kumar et al.
14 reported decreased CD34 yields and an increase in number of apheresis collections in patients treated with lenalidomide compared with those receiving thalidomide and dexamethasone or VAD regimens. Furthermore, an inverse correlation was seen between stem cell yield and duration of lenalidomide therapy. Mazumder et al. 15 confirmed these results of lower stem cell yield with 12 of 28 patients failing to collect sufficient stem cells (o2 Â 10 6 CD34 þ /kg) for even a single transplant. In addition, three patients failed to mobilize with a subsequent AMD3100 þ G-CSF compassionate use of protocol. Although chemotherapy with G-CSF regimens may be considered in patients receiving lenalidomide upfront, chemomobilization is associated with increased toxicity because of the regimen itself and with higher resource utilization because of the difficulties in optimal timing of stem cell harvest.
In earlier studies of HDCT, patients achieving CR post transplant had longer EFS and DFS compared with those who did not. Currently, therefore, there is interest in using immunomodulatory drugs and bortezomib in combination regimens to maximize depth of response post transplant. Recent randomized studies have shown that the response rates achieved after autologous transplant were similar when either thalidomide and dexamethasone or VAD were used as pre-transplant induction therapy. 16 In contrast, combination therapy with bortezomib and dexamethasone had higher CR þ VGPR rates post transplant when compared with VAD chemotherapy (62 versus 42%, Po0.0001). 17 Similarly, combination therapy with bortezomib, thalidomide and dexamethasone produced superior CR þ VGPR rates post transplant when compared with thalidomide and dexamethasone alone (77 versus 54%). 18 Unfortunately, follow-up as reported is short, and currently the impact of these different induction regimens on EFS and OS survival is not known. In our series, we report that 43% had a CR þ VGPR post transplant and we provide a median of 27 months F/U data on a bortezomibcontaining pre-transplant regimen.
A number of agents have been tested in the post transplant setting to improve both the depth and durations of responses. IFN-a with or without steroids has been studied extensively both with standard and HDCT with variable benefit for PFS but no improvement in OS. [19] [20] [21] [22] Alternative day dosing prednisone improved OS after conventional therapy but is not well tolerated or accepted by patients or physicians. 23 Among newer agents, Attal et al. 24 showed that thalidomide maintenance for 1 year increases both 3-year EFS (37-52%, Po0.009) and OS (87 versus 75% at 4 years, P ¼ 0.04). However, this advantage was limited to individuals who attained less than VGPR after HDCT. In addition, no benefit was seen in patients with a del13 karyotype. Here, we show the feasibility of post transplant bortezomib therapy in multiple myeloma. We chose a once-weekly regimen of administration in the post transplant period for convenience. The schedule of weekly bortezomib 1.3 g/m 2 is well tolerated without adverse hematologic effects or a significant worsening of peripheral neuropathy. By using this dose of bortezomib, we did not see any appreciable drop in paraprotein levels. Other investigators have reported on the clinical activity of bortezomib 1.6 g/m 2 in myeloma. 25, 26 However, our trial was designed before data on the higher once-weekly dose regimen became available. It is difficult to make definitive conclusions on the longterm benefit of bortezomib administered post transplant. The EFS of 25.7 months observed in this study with bortezomib maintenance is similar to previously published studies of a single autologous transplantation. 1, 2, 27 The fact that thalidomide maintenance did not improve survival in patients who had already achieved a VGPR with HDCT has been suggested by some to mean that thalidomide acts as consolidation therapy rather than maintenance therapy in the post transplant setting. 24 It is plausible that schedules of bortezomib, which are more successful in increasing the depth of response post transplant, may lead to better long-term outcomes. Such studies are currently ongoing.
Although the anti-myeloma effect of bortezomib is not fully understood, the anti-proteasomal activity of bortezomib inhibits nuclear factor-kB and the downstream expression of genes critical for cell survival. 28 Nuclear factor-kB is implicated in the regulation of many genes that code for mediators of the immune and inflammatory response. Bortezomib has been shown to potently inhibit in vitro MLR and promote apoptosis of alloreactive T cells. In a murine model, this led to inhibition of GVHD with retention of graft versus tumor effects. 29 However, the same authors showed that the delayed administration of bortezomib resulted in increased GVHD-dependent gastrointestinal toxicity. 30 Bortezomib may be explored as an agent to modulate graft-versus-host and graft-versus-malignancy effects.
In this study, the analysis of peripheral lymphocyte subsets suggests that bortezomib is selectively toxic to normal cytotoxic CD8 þ T cells and natural killer cells. Bortezomib has shown clinical activity against a number of lymphoid malignancies including mantle cell lymphoma, follicular and peripheral T-cell non-Hodgkin's lymphoma. 31, 32 In addition, bortezomib has been shown to reduce circulating CD3 þ T cells when administered post-allogeneic transplant in patients with myeloma. 33 As cellmediated immune responses are important in controlling primary VZV infection and maintaining viral latency, the effect of bortezomib on normal CD8 þ and CD56 þ lymphocyte subsets may explain the high rate of viral reactivation. 34 High rates of VZV reactivation have been noted in both phase II and phase III studies of bortezomib. In the Assessment of Proteasome Inhibition for Extending Remissions study, VZV reactivation was seen in 13% in the bortezomib arm compared with 5% in the dexamethasone arm. 35 Our data suggest that patients post transplant may be at higher risk for developing reactivation. This information may have a particular impact in ongoing studies that incorporate bortezomib in the post transplant setting both in multiple myeloma and in diseases such as mantle cell lymphoma. For these patients, more prolonged routine viral prophylaxis with acyclovir or valacyclovir may result in lower rates of virus reactivation.
In conclusion, our study adds to the growing literature that, unlike lenalidomide, pre-transplant induction therapy with bortezomib has no adverse impact on the mobilization of autologous stem cells. With short-duration acyclovir prophylaxis, bortezomib administration in the peri-transplant period resulted in high rates of reactivation of herpes zoster. Interpretation of the role of bortezomib maintenance in myeloma based on this single study is limited because of the relatively small sample size and relatively short duration of maintenance therapy. Larger prospective randomized studies of post transplant bortezomib are required and are currently ongoing.
